Cancer Stem Cell News Volume 9.04 | Feb 05 2020

TOP STORY

Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer

Tumors with high AXL, TGF-β and JAK1 signaling concomitantly displayed CD133-mediated cancer stemness and hybrid EMT features in advanced stage patients, suggesting greater potential for distant dissemination. [Cancer Res] Abstract

(Ranked by impact factor of the journal)

Targeting of Plasminogen Activator Inhibitor-1 Activity Promotes Elimination of Chronic Myeloid Leukemia Stem Cells

Scientists showed that selective blockade of plasminogen activator inhibitor-1 enhanced the susceptibility of chronic myeloid leukemia-leukemic stem cells (CML-LSCs) to tyrosine kinase inhibitor, which facilitated the eradication of CML-LSCs and led to sustained remission of the disease. [Haematologica] Abstract

LncRNA RUNX1-IT1 Which Is Downregulated by Hypoxia-Driven Histone Deacetylase 3 Represses Proliferation and Cancer Stem-Like Properties in Hepatocellular Carcinoma Cells

RUNX1-IT1 repressed hepatocellular carcinoma cell proliferation, cell cycle progression, invasion and cancer stemness and induced apoptosis in vitro. [Cell Death Dis] Full Article

TfR1 Binding with H-Ferritin Nanocarrier Achieves Prognostic Diagnosis and Enhances the Therapeutic Efficacy in Clinical Gastric Cancer

Transferrin receptor 1 (TfR1)-negative sorted cells exhibited tumor-initiating features, which enhanced tumor formation and migration/invasion, whereas TfR1-positive sorted cells showed significant proliferation ability. [Cell Death Dis] Full Article

DNMT3A Mutants Provide Proliferating Advantage with Augmentation of Self-Renewal Activity in the Pathogenesis of AML in KMT2A-PTD-Positive Leukemic Cells

Researchers found that overexpression of DNMT3A mutants in histone-lysine N-methyltransferase (KMT2A-PTD)-positive EOL-1 cells augmented cell proliferation and clonogenicity. [Oncogenesis] Full Article

The Mechanism of How CD95/Fas Activates the Type I IFN/STAT1 Axis, Driving Cancer Stemness in Breast Cancer

Chronic stimulation of CD95 on breast cancer cells could increase their cancer initiating capacity through activation of a type I interferon/STAT1 pathway when caspases were inhibited. [Sci Rep] Full Article

Cucurbitacin B and I Inhibits Colon Cancer Growth by Targeting the Notch Signaling Pathway

Scientists investigated the effects of cucurbitacin B or I, a natural compound that exists in edible plants, against colorectal cancer. Cucurbitacin B or cucurbitacin I inhibited proliferation, clonogenicity, induced G₂/M cell-cycle arrest and caspase-mediated-apoptosis of colorectal cancer cells. [Sci Rep] Full Article

NFкB Is a Critical Transcriptional Regulator of Atypical Cadherin FAT1 in Glioma

Characterization of FAT1 promoter for transcriptional regulation was performed by in vitro functional assays using promoter deletion constructs, site directed mutagenesis and ChIP in glioblastoma cells. [BMC Cancer] Full Article

TRIB3 Confers Glioma Cell Stemness via Interacting with β-Catenin

Investigators explored whether tribbles pseudokinase 3 (TRIB3) enhanced glioma cell stemness. TRIB3 was overexpressed in glioma tissues and cell-formed spheres, positively correlated with the size and grade. [Environ Toxicol] Abstract

Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News.

Glioblastoma Stem Cells: Driving Resilience through Chaos

Analyzing the transcriptional, epigenetic, and metabolic landscapes of glioblastoma stem cell (GSC) dynamics in the context of a stochastically fluctuating tumor network will provide novel strategies to target resistant populations of GSCs in glioblastoma. [Trends Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Moleculin Announces Successful Completion of US Phase I AML Trial of Annamycin

Moleculin Biotech, Inc. announced that its open label, single arm US Phase I trial met its primary objective of demonstrating the safety of Liposomal Annamycin in treating relapsed or refractory acute myeloid leukemia. [Moleculin Biotech, Inc.] Press Release

AbbVie Receives Positive CHMP Opinion for VENCLYXTO^® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia

AbbVie, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for VENCLYXTO^® in combination with obinutuzumab for the treatment of patients with chronic lymphocytic leukemia who were previously untreated. [AbbVie, Inc.] Press Release

US Prosecutor Leading China Probe Explains Effort That Led to Charges against Harvard Chemist

The US government isn’t prosecuting Charles Lieber because he’s a world-renowned inorganic chemist at Harvard University, says the US attorney who last week drew headlines by charging Lieber with making false statements about his ties to Chinese research institutions. Nor does the Department of Justice think for one minute that Lieber is a spy. [ScienceInsider] Editorial

Cash From Cannabis Companies Creates Conflicted Researchers

Imagine that scientists charged with doing research on tobacco’s health implications were funded by tobacco companies. In fact, the tobacco industry used this tactic for decades to cast doubt on the adverse health effects of smoking. But today it would be an outrageous conflict of interest – research on addictive drugs shouldn’t be paid for by people who stand to profit from selling them. Yet this is exactly what is happening with cannabis. [STAT News] Editorial

NEW Gene and Cell Based Therapies: CRISPR, Stem Cells, and Beyond
March 2-4, 2020
San Francisco, California, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Translational Brain Tumor Research (Northwestern University)

Postdoctoral Studentship and PhD Position – Cancer Cell Plasticity (Giessen University)

Postdoctoral Position – Stemness in Epigenetic Regulation (University of Freiburg)

Postdoctoral Fellow – Research in Cancer Progression (The Wistar Institute)

Postdoctoral Position – Bioinformatics and Leukemia Stem Cells (The Centre for Genomic Regulation)

Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute)

Team Leader – Clonal Evolution in Leukemia (Institute of Cancer Research)

Research Fellow – Glioblastoma Cell Signaling (University of Sussex)

Postdoctoral Associate – Leukemia and Brain Tumors (Ann and Robert H. Lurie Children’s Hospital of Chicago)

Postdoctoral Position – Glioma and Neurodevelopment (Mount Sinai)

Postdoctoral Scholarship – Brain Tumor Stemness (Lund University)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.